PTC THERAPEUTICS, INC. 8-K

What Happened

• PTC Therapeutics, Inc. announced on June 15, 2026 that it priced an offering of $500.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2031 (the “Notes”). The company granted initial purchasers a 13‑day option to buy up to an additional $50.0 million of Notes.
• The press release announcing the pricing is attached to the Form 8-K (Exhibit 99.1). The company filed the Form 8-K on June 16, 2026.

Key Details

• Offering size: $500.0 million principal amount of 0.00% convertible senior notes due 2031, plus an option for up to $50.0 million more.
• Use of proceeds: Approximately $328.8 million of net proceeds expected to be used to repurchase $222.0 million aggregate principal of the company’s outstanding 1.5% Convertible Senior Notes due 2026 via privately negotiated transactions entered concurrently with the pricing.
• Remaining proceeds: For general corporate purposes, which may include additional repurchases of the 2026 Notes or repayment at maturity.
• Registration and timing: The Notes and any shares issuable on conversion have not been and will not be registered under the Securities Act; the filing notes there is no assurance the Offering will be completed on the anticipated terms.

Why It Matters

• This financing reshapes PTC’s near-term debt profile by replacing a portion of its 2026 convertible notes with new 2031 convertible notes at a 0.00% coupon, which could reduce near-term interest expense and extend maturities if the Offering closes as planned.
• Investors should note the Offering is subject to completion and securities considerations (conversion shares not registered); the company’s stated use of proceeds is targeted but not guaranteed and the filing is not a notice of redemption or general offer to repurchase remaining 2026 notes.